Hepatic osteodystrophy

Clinical Cases in Mineral and Bone Metabolism

Volumn 11, Issue 3, 2014, Pages 185-191

  Gatta, Angelo ^a   Verardo, Alberto ^a   Di Pascoli, Marco ^a   Giannini, Sandro ^a   Bolognesi, Massimo ^a  

^a UNIVERSITY OF PADOVA   (Italy)

Author keywords

Hepatic osteodystrophy; Liver cirrhosis; Liver transplantation; Vitamin D

Indexed keywords

VITAMIN D;

ALCOHOL CONSUMPTION; ARTICLE; BONE DENSITY; CHRONIC LIVER DISEASE; EXERCISE; HEPATIC OSTEODYSTROPHY; HUMAN; LIVER TRANSPLANTATION; METABOLIC DISORDER; MINERAL SUPPLEMENTATION; OSTEODYSTROPHY; OSTEOPOROSIS; PATHOGENESIS; SMOKING CESSATION; VITAMIN D DEFICIENCY; VITAMIN SUPPLEMENTATION;

EID: 84919328013     PISSN: 17248914     EISSN: 19713266     Source Type: Journal    
DOI: 10.11138/ccmbm/2014.11.3.185     Document Type: Article

References (123)

1. Nakchbandi IA, van der Merwe SW. Current understanding of osteoporosis associated with liver disease. Nat Rev Gastroenterol Hepatol. 2009;6:660-670.
2. Rouillard S, Lane NE. Hepatic Osteodystrophy. Hepatology. 2001;33:301-307.
3. Pusl T, Beuers U. Extrahepatic manifestations of cholestatic liver diseases: pathogenesis and therapy. Clin Rev Allergy Immunol. 2005;28:147-157.
4. Marignani M, Angeletti S, Capurso G, Cassetta S, Delle Fave G. Bad to the bone: the effects of liver diseases on bone. Minerva Med. 2004;95:489-505.
5. Compston JE, Thompson RPH. Intestinal absorption of 25-hydroxyvitamin D and osteomalacia in primary biliary cirrhosis. Lancet. 1977;309:721-724.
6. López-Larramona G, Lucendo AJ, Gonzàlez-Castillo S, Tenias JM. Hepatic osteoystrophy: an important matter for consideration in chronic liver disease. World J Hepat. 2011;3:300-307.
7. Matloff DS, Kaplan MM, Neer RM, Goldberg MT, Bitman W, Wolfe HJ. Osteoporosis in primary Edizioni biliary cirrhosis: effects of 25-hydroxyvitamin D treatment. Gastroenterology. 1982;83:97-102.
8. Lalor BC, France MW, Powell D, Adams PH, Counichan TB. Bone and mineral metabolism and chronic alcohol abuse. QJ Med. 1986;59:497-511.
9. Collier J. Bone disorders in chronic liver disease. Hepatology. 2007;46:1271-1278.
10. Giouleme OI, Vyzantiadis TA, Nikolaidis NL, Vasiliadis TG, Papageorgiou AA, Eugenidis NP, Harsoulis FI. Pathogenesis of osteoporosis in liver cirrhosis. Hepatogastroenterology. 2006;53(72):938-943.
11. Wariaghli G, Allali F, El Maghraoui A, Hajjaj-Hassouni N. Osteoporosis in patients with primary biliary cirrhosis. Eur J Gastroenterol Hepatol. 2010;22:1397-1101.
12. Gasser RW. Cholestasis and metabolic bone disease - a clinical review. Wien Med Wochenschr. 2008;158:553-557.
13. Van Berkum FN, Beukers R, Birkenhäger JC, Kooij PP, Schalm SW, Pols HA. Bone mass in women with primary biliary cirrhosis: the relation with histological stage and use of glucocorticoids. Gastroenterology. 1990;99:1134-1139.
14. Parés A, Guañabens N. Osteoporosis in primary biliary cirrhosis: pathogenesis and treatment. Clin Liver Dis. 2008;12:407-424.
15. Angulo P, Therneau TM, Jorgensen A, DeSotel CK, Egan KS, Dickson ER, Hay JE, Lindor KD. Bone disease in patients with primary sclerosing cholangitis: prevalence, severity and prediction of progression. J Hepatol. 1998;29:729-735.
16. Goral V, Simsek M, Mete N. Hepatic osteodystrophy and liver cirrhosis. World J Gastroenterol. 2010;16:1639-1643.
17. Pereira FA, Facincani I, Jorgetti V, Ramalho LN, Volpon JB, Dos Reis LM, de Paula FJ. Etiopathogenesis of hepatic osteodystrophy in Wistar rats with cholestatic liver disease. Calcif Tissue Int. 2009;85:75-83.
18. Goel V, Kar P. Hepatic Osteodystrophy. Trop Gastroenterol. 2010;31:82-86.
19. George J, Ganesh HK, Acharya S, Bandgar TR, Shivane V, Karvat A, Bhatia SJ, Shah S, Menon PS, Shah N. Bone mineral density and disorders of mineral metabolism in chronic liver disease. World J Gastroenterol. 2009;15:3516-3522.
20. Janes CH, Dickson ER, Okazaki R, Bonde S, McDonagh AF, Riggs BL. Role of hyperbilirubinemia in the impairment of osteoblast proliferation associated with cholestatic jaundice. J Clin Invest. 1995;95:2581-2586.
21. Weinreb M, Pollak RD, Ackerman Z. Experimental cholestatic liver disease through bile-duct ligation in rats results in skeletal fragility and impaired osteoblastogenesis. J Hepatol. 2004;40:385-390.
22. Mounach A, Ouzzif Z, Wariaghli G, Achemlal L, Benbaghdadi I, Aouragh A, Bezza A, El Maghraoui A. Primary biliary cirrhosis and osteoporosis: a case-control study. J Bone Miner Metab. 2008;26:379-384.
23. Gonzalez-Calvín JL, Garcia-Sanchez A, Bellot V, Muñoz-Torres M, Raya-Alvarez E, Salvatierra-Rios D. Mineral metabolism, osteoblastic function and bone mass in chronic alcoholism. Alcohol Alcohol. 1993;28:571-579.
24. Kim MJ, Shim MS, Kim MK, Lee Y, Shin YG, Chung CH, Kwon SO. Effect of chronic alcohol ingestion on bone mineral density in males without liver cirrhosis. Korean J Intern Med. 2003;18:174-180.
25. Santolaria F, Gonzalez-Reimers E, Pérez-Manzano JL, Milena A, Gòmez-Rodrìguez MA, Gonzàlez-Diaz A, de la Vega MJ, Martinez-Riera A. Osteopenia assessed by body composition analysis is related to malnutrition in alcoholic patients. Alcohol. 2000;22:147-157.
26. Gonzalez-Reimers E, Alvisa-Negrin J, Santolaria-Fernàndez F, Ros-Vilamajò R, Martìn-Gonzàlez MC, Hernàndez-Betancor I, Garcia-Valdecasas-Campelo E, Gonzàlez-Diaz A. Prognosis of osteopenia in chronic alcoholics. Alcohol. 2011;45:227-238.
27. Hay JE, Guichelaar MM. Evaluation and management of osteoporosis in liver disease. Clin Liver Dis. 2005;9:747-766.
28. Lacey DL, Timms E, Tan HL, Kelley MJ, Dunstan CR, Burgess T, Elliott R, Colombero A, Elliott G, Scully S, Hsu H, Sullivan J, Hawkins N, Davy E, Capparelli C, Eli A, Qian YX, Kaufman S, Sarosi I, Shalhoub V, Senaldi G, Guo J, Delaney J, Boyle WJ. Osteoprotegerin ligand is a cytokine that regulates osteoclast differentiation and activation. Cell. 1998;98:165-176.
29. Hofbauer LC, Heufelder AE. Role of receptor activator of nuclear factor κB ligand and osteoprotegerin in bone cell biology. J Mol Med. 2001;79:243-253.
30. Monegal A, Navasa M, Peris P, Alvarez L, Pons F, Rodés J, Guañabens N. Serum osteoprotegerin and its ligand in cirrhotic patients referred for orthotopic transplantation: relationship with metabolic bone disease. Liver Int. 2007;27:492-497.
31. Moschen AR, Kaser A, Stadlmann S, Millonig G, Kaser S, Muhllechner P, Habior A, Graziadei I, Vogel W, Tilg H. The RANKL/OPG system and bone mineral density in patients with chronic liver disease. J Hepat. 2005;43:973-983.
32. Szalay F, Hegedus D, Lakatos PL, Tornai I, Bajnok E, Dunkel K, Lakatos P. High serum osteoprotegerin and low RANKL in primary biliary cirrhosis. J Hepat. 2003;38:395-400.
33. Hegedus D, Ferencz V, Lakatos PL, Meszaros S, Lakatos P, Horvath C, Szalay F. Decreased bone density, elevated serum osteoprotegerin, and β-cross-laps in Wilson disease. J Bone Min Res. 2002;17:1961-1967.
34. Schett G, Kiechl S, Redlich K, Oberhollenzer F, Weger S, Egger G, Mayr A, Jocher J, Xu Q, Pietschmann P, Teitelbaum S, Smolen J, Willeit J. Soluble RANKL and risk of nontraumatic fracture. J Am Med Ass. 2004;291:1108-1113.
35. O'Gradaigh D, Ireland D, Bord S, Compston JE. Joint erosion in rheumatoid arthritis: interactions between tumor necrosis afctor alpha, interleukin 1, and receptor activator of nuclear factor kappaB ligand (RANKL) regulate osteoclasts. Ann Rheum Dis. 2004;63:354-359.
36. Komine M, Kukita A, Kukita T, Ogata Y, Hotokebuchi T, Kohashi O. Tumor necrosis factor-alpha cooperates with receptor activator of nuclear factor kappaB ligand in generation of osteoclasts in stromal cell-depleted rat bone marrow cell culture. Bone. 2001;28:474-483.
37. Wang X, Luo Y, Liao WB, Zhang J, Chen TM. Effect of osteoprotegerin in combination with interleukin-6 on inhibition of osteoclast differentiation. Chin J Traumatol. 2013;16:277-280.
38. Suda T, Kobayashi K, Jimi E, Udagawa N, Takahashi N. The molecular basis of osteoclast differentiation and activation. Novartis Found Symp. 2001;232:235-247.
39. Jia D, O'Brien CA, Stewart SA, Manolagas SC, Weinstein RS. Glucocorticoids act directly on osteoclasts to increase their life span and reduce bone density. Endocrinology. 2006;14:5592-5599.
40. Saag KG. Glucocorticoid-induced osteoporosis. Endocrinol Metab Clin North Am. 2003;32:135-157.
41. McCaughan GW, Feller RB. Osteoporosis in chronic liver disease: pathogenesis, risk factors, and management. Dig Dis. 1994;12:223-231.
42. Collier J. Bone disorders in chronic liver disease. Hepatology. 2007;46:1271-1278.
43. Weinstein RS, Jilka RL, Parfitt AM, Manolagas SC. Inhibition of osteoblastogenesis and promotion of apoptosis of osteoblasts and osteocytes by glucocorticoids - potential mechanisms of their deleterious effects on bone. J Clin Invest. 1998;102:274-282.
44. Diamond T, Stiel D, Posen S. Osteoporosis in hemochromatosis: iron excess, gonadal deficiency, or other factors? Ann Intern Med. 1989;110:430-436.
45. Bell H, Raknerud N, Falch JA, Haug E. Inappropriately low levels of gonadotrophins in amenorrhoeic women with alcoholic and non-alcoholic cirrhosis. Eur J Endocrinol. 1995;132:444-449.
46. Seeman E. The structural and biomechanical basis of the gain and loss of bone strength in women and men. Endocrinol Metab Clin North Am. 2003;32:25-38.
47. Hay JE. Bone disease in cholestatic liver disease. Gastroenterology. 1995;108:276-283.
48. Hiruma Y, Nakahama K, Fujita H, Morita I. Vitamin K2 and geranylgeraniol, its side chain component, inhibited sosteoclast formation in a different manner. Biochem Biophys Res Commun. 2004;314:24-30.
49. Koshihara Y, Hoshi K, Okawara R, Ishibashi H, Yamamoto S. Vitamin K stimulates osteoblastogenesis and inhibits osteoclastogenesis in human bone marrow cell culture. J Endocrinol. 2003;176:339-348.
50. Nishiguchi S, Shimoi S, Kurooka H, Tamori A, Habu D, Takeda T, Kubo S. Randomized pilot trial of vitamin K2 for bone loss in patients with primary biliary cirrhosis. J Hepatol. 2001;35:543-545.
51. Cockayne S, Adamson J, Lanham-new S, Shearer MJ, Gilbody S, Torgerson DJ. Vitamin K and prevention of fractures: systematic review and meta-analysis of randomized controlled trials. Arch Intern Med. 2006;166:1256-1261.
52. Arteh J, Narra S, Nair S. Prevalence of vitamin D deficiency in chronic liver disease. Dig Dis Sci. 2010;55:2624-2628.
53. Collier JD, Ninkovic M, Compston JE. Guidelines on the management of osteoporosis associated with chronic liver disease. Gut. 2002;50:1-9.
54. EASL. EASL clinical practice guidelines: management of cholestatic liver disease. J Hepatol. 2009;51:237-267.
55. Zollner G, Trauner M. Nuclear receptors as therapeutic targets in cholestatic liver diseases. Edizioni Br J Pharmacol. 2009;156:7-27.
56. Högler W, Baumann U, Kelly D. Endocrine and bone metabolic complications in chronic liver disease and after liver transplantation in children. JPGN. 2012;54:313-321.
57. Fisher L, Fisher A. Vitamin D and parathyroid hormone in outpatients with noncholestatic chronic liver disease. Clin Gastroenterol Hepatol. 2007;5:513-520.
58. Cholongitas E, Theocharidou E, Goulis J, Tsochatzis E, Akriviadis E, Burroughs AK. Review article: the extra-skeletal effects of vitamin D in chronic hepatitis C infection. Aliment Pharmacol Ther. 2012;35:634-646.
59. Malik P, Gasser RW, Kemmler G, Moncayo R, Finkenstedt G, Kurz M, Fleischhacker WW. Low bone mineral density and impaired bone metabolism in young alcoholic patients without liver cirrhosis: a cross-sectional study. Alcohol Clin Exp Res. 2009;33:375-381.
60. Lips P. Vitamin D deficiency and secondary hyperparathyroidism in the elderly: consequences for bone loss and fractures and therapeutic implications. Endocr Rev. 2001;22:477-501.
61. Rode A, Fourlanos S, Nicoll A. Oral vitamin D replacement is effective in chronic liver disease. Gastroenterol Clin Biol. 2010;34:618-620.
62. Springer JE, Cole DE, Rubin LA, Cauch-Dudek K, Harewod L, Evrovski J, et al. Vitamin D -receptor genotypes as independent genetic predictors of decreased bone mineral density in primary biliary cirrhosis. Gastroenterology. 2000;118:145-151.
63. Parés A, Guañabens N, Rodés J. Gene polymorphisms as predictors of decreased bone mineral density and osteoporosis in primary biliary cirrhosis. Eur J Gastroenterol Hepatol. 2005;17:311-315.
64. Ruppe MD. Medications affect calcium. Endocr Pract. 2011;17 Suppl.1: 26-30.
65. Herlong HF, Recker RR, Maddrey WC. Bone disease in primary biliary cirrhosis: histologic features and response to 25-hydroxyvitamin D. Gastroenterology. 1982;83:103-108.
66. Reed JS, Meredith SC, Nemchausky BA. Bone disease in primary biliary cirrhosis: reversal of osteomalacia with oral 25-hydroxyvitamin D. Gastroenterology. 1980;78:513-517.
67. Bitetto D, Fabris C, Falleti E, Fornasiere E, Fumolo E, Fontanini E, Cussigh A, Occhino G, Baccarani U, Pirisi M, Toniutto P. Vitamin D and the risk of acute allograft rejection following human liver transplantation. Liver Int. 2010;30:417-444.
68. Corey KE, Zheng H, Mendez-Navarro J, Delgado-Borrego A, Dienstag JL, Chung RT, HALT-C Trial Group. Serum vitamin D levels are not predictive of the progression of chronic liver disease in hepatitis C patients with advanced fibrosis. PloS ONE. 2012;7:e27144.
69. Crosbie OM, Freaney R, McKenna MJ, Curry MP, Hegarty JE. Predicting bone loss following orthotopic liver transplantation. Gut. 1999;44:430-434.
70. Wibaux C, Legroux-Gerot I, Dharancy S, Boleslawski E, Declerck N, Canva V, Mathurin P, Pruvot FR, Cortet B. Assessing bone status in patients awaiting liver transplantation. Joint Bone Spine. 2011;78:387-391.
71. Leslie WD, Bernstein CN, Leboff MS. AGA technical review on osteoporosis in hepatic disorders. Gastroenterology. 2003;125:941-966
72. Compston JE. Osteoporosis after liver transplantation. Liver Transpl. 2003;9:321-330.
73. Ebeling PR. Approach to the patient with transplantation-related bone loss. J Clin Endocrinol Metab. 2009;94:1483-1490.
74. Monegal A, Navasa M, Guañabens N, Peris PP, Pons F, Martinez de Osaba MJ, Rimola A, Rodés J, Muñoz-Gòmez J. Osteoporosis and bone mineral metabolism disorders in cirrhotic patients referred for orthotopic liver transplantation. Calcif Tissue Int. 1997;60:148-154.
75. Luxon BA. Bone disorders in chronic liver diseases. Curr Gastroenterol Rep. 2011;13:40-48.
76. Millonig G, Graziadei IW, Eichler D, Pfeiffer KP, Finkenstedt G, Muehllechner P, Koenigsrainer A, Margreiter R, Vogel W. Alendronate in combination with calcium and vitamin D prevents bone loss after orthotopic liver transplantation: a prospective single-center study. Liver Transpl. 2005;11:960-966.
77. Atamaz F, Hepguler S, Akyildiz M, Karasu Z, Kilic M. Effects of alendronate on bone mineral density and bone metabolic markers in patients with liver transplantation. Osteoporos Int. 2006;17:942-949.
78. Dodidou P, Bruckner T, Hosch S, Haass M, Klar E, Sauer P, Ziegler R, Lei-dig-Bruckner G. Better late than ever? Experience with intravenous pamidronate treatment in patients with low bone mass or fractures following cardiac or liver transplantation. Osteoporos Int. 2003;14:82-89.
79. Monegal A, Guañabens N, Suárez MJ, Suárez F, Clemente G, García-González M, De la Mata M, Serrano T, Casafont F, Tome S, Barrios C, Navasa M. Pamidronate in the prevention of bone loss after liver transplantation: a randomized controlled trial. Transpl Int 2009;22:198-206.
80. Pennisi P, Trombetti A, Giostra E, Mentha G, Rizzoli R, Flore CE. Pamidronate and osteoporosis prevention in liver transplant recipients. Rheumatol Int. 2007;27:251-256.
81. Guadalix S, Martinez-Diaz-Guerra G, Lora D, Vargas C, Gòmez-Juaristi M, Cobaleda B, Gonzalez EM, Hawkins F. Effect of early risendronate treatment on bone mineral density and bone turnover markers after liver transplantation: a prospective single-center study. Transpl Int. 2011;24:657-665.
82. Crawford BA, Kam C, Pavlovic J, Byth K, Handelsman DJ, Angus PW, McCaughan GW. Zoledronic acid prevents bone loss after liver transplantation: a randomized, double-blind, placebo-controlled trial. Ann Intern Med. 2006;144:239-248.
83. Shane E, Cohen A, Stein EM, McMahon DJ, Zhang C, Young P, Pandit K, Staron RB, Verna EC, Brown R, Restaino S, Mancini D. Zoledronic acid versus alendronate for the prevention of bone loss after heart or liver transplantation. J Clin Endocrinol Metab. 2012;97:4481-4490.
84. Bodingbauer M, Wekerle T, Pakrah B, Roschger P, Peck-Radosavljevic M, Silberhumer G, Grampp S, Rockenschaub S, Berlakovich G, Steininger R, Klaushofer K, Oberbauer R, Muhlbacher F. Prophylactic bisphosphonates treatment prevents bone fractures after liver transplantation. Am J Transplant. 2007;7:1763-1769.
85. Misof BM, Bodingbauer M, Roschger P, Wekerle T, Pakrah B, Haas M, Kainz A, Oberbauer R, Muhlbachter F, Kalushofer K. Short-term effects of highdose zoledronic acid treatment on bone minera-lization density distribution after orthotopic liver transplantatio. Calcif Tissue Int. 2008;83:167-175.
86. McDonald JA, Dunstan CR, Dilworth P, Sherbon K, Shell AG, Evans RA, McCaughan GW. Bone loss after liver transplantation. Hepatology. 1991;14:613-619.
87. Meys E, Fontages E, Fourcade N, Thomasson A, Pouyet M, Delmas P. Bone loss after orthotopic liver transplantation. Am J Med. 1994;97:445-450.
88. Cunningham J. Post-transplantation bone disease. 2005;79:629-634.
89. Edwards BJ, Desai A, Tsai J, Du H, Edwards GR, Bunta AD, Hahr A, Abecassis M, Sprague S. Elevated incidence of fractures in solid-organ transplant recipients on glucocorticoid-sparing immunosoppressive regimens. J Osteoporos. 2011;2011:591793.
90. Guichelaar MMJ, Schmoll J, Malinchoc M, Hay JE. Fractures and avascular necrosis before and after orthotopic liver transplantation: long-term followup and predictive factors. Hepatology. 2007;46:1198-1207.
91. Carey EJ, Balan V, Kremers WK, Hay JE. Osteopenia and osteoporosis in patients with end-stage liver disease caused by hepatitis C and alcoholic liver disease: not just a cholestatic problem. Liver Transplantation. 2003;9:1166-1173.
92. Weinstein RS, Chen JR, Powers CC, Stewart SA, Landes RD, Bellido T, Jilka RL, Parfitt AM, Manolagas SC. Promotion of osteoclast survival and antagonism of bisphosphonate-induced osteoclast apoptosis by glucocorticoids. J Clin Invest. 2002;109:1041-1048.
93. Högler W, Baumann U, Kelly D. Growth and bone health in chronic liver disease and following liver transplantation in children. Pediatr Endocrinol Rev. 2010;7:266-274.
94. Cvetkovic M, Mann GN, Romero DF, Liang XG, Ma Y, Jee WS, Epstein S. The deleterious effects of long-term cyclosporine A, cyclosporine G, and FK506 on bone mineral metabolism in vivo. Transplantation. 1994;57:1231-1237.
95. Epstein S. Post-transplantation bone disease: the role of immunosuppressive agents and the skeleton. J Bone Min Res. 1996;11:1-7.
96. Compston JE. Hepatic osteodystrophy: vitamin D metabolism in patients with liver disease. Gut. 1986;27:1073-1090.
97. Floreani A, Fries W, Luisetto G, Burra P, Fagiuoli S, Boccagni P, Della Rovere GR, Plebani M, Piccoli A, Naccarato R. Bone metabolism in orthotopic liver transplantation: a prospective study. Liver Transpl Surg. 1998;4:311-319.
98. Compston JE, Greer S, Skingle SJ, Stirling DM, Price C, Friend PJ, Alexander G. Early increase in plasma parathyroid hormone levels following liver transplantation. J Hepatol. 1996;25:715-718.
99. Monegal A, Navasa M, Guanabens N, Peris P, Pons F, Martinez de Osaba MJ, Ordi J, Rimola A, Rodés J, Muñoz-Gòmez J. Bone disease after liver transplantation: a long-term prospective study of bone mass changes, hormonal status and histomorphometric characteristics. Osteoporos Int. 2001;12:484-492.
100. Abdelhadi M, Eriksson Edizioni SA, Eriksson SL, Ericzon BG, Nordenstrom J. Bone mineral status in end-stage liver disease and the effect of liver transplantation. Scand J Gastroenterol. 1995;30:1210-1215.
101. Floreani A, Mega A, Tizian L, Burra P, Boccagni P, Valdo V, Fagiuoli S, Naccarato R, Luisetto G. Bone metabolism and gonad function in male patients undergoing liver transplantation: a two-year longitudinal study. Osteoporos Int. 2001;12:749-754.
102. Szarvas F, Julesz J, Toth I, Faredin I. Hypogonadism in male patients with chronic liver disease. Z Gesamte Inn Med. 1975;30:254-256.
103. Foresta C, Schipilliti M, Ciarleglio FA, Lenzi A, D'Amico D. Male hypogonadism in cirrhosis and after liver transplantation. J Endocrinol Invest. 2008;31:470-478.
104. Ninkovic M, Skingle SJ, Bearcroft PW, Bishop N, Alexander GJ, Compston JE. Incidence of vertebral fractures in the first three month after orthotopic liver transplantation. Eur J Gastroenterol Hepatol. 2000;12:931-935.
105. Leidig-Bruckner G, Hosch S, Dodidou P, Ritschel D, Conradt C, Klose C, Otto G, Lange R, Theilmann L, Zimmerman R, Pritsch M, Ziegler R. Frequency and predictors of osteoporotic fractures after cardiac or liver transplantation: a follow-up study. Lancet. 2001;357:342-347.
106. Feller RB, McDonald JA, Sherbon KJ, McCaughan GW. Evidence of continuing bone recovery at a mean of 7 years after liver transplantation. Liver Transpl Surg. 1999;5:407-413.
107. Giannini S, Nobile M, Ciuffreda M, Iemmolo RM, Dalle Carbonare L, Minicuci N, Casagrande F, Destro C, Gerunda GE, Sartori L, Crepaldi G. Longterm persistence of low bone density in orthotopic liver transplantation. Osteoporos Int. 2000;11:417-424.
108. Labio ED, Del Rosario DB, Strasser SI, McCaughan GW, Crawford BA. Effect of ascites on bone density measurement in cirrhosis. J Clin Densitom. 2007;10:391-394.
109. Guañabens N, Monegal A, Muxi A, Martinez-Ferrer A, et al. Patients with cirrhosis and ascites have false values of bone density: implications for the diagnosis of osteoporosis. Osteoporos Int. 2012;23:1481-1487.
110. Mansueto P, Carroccio A, Seidita A, Di Fede G, Craxì A. Osteodystrophy in chronic liver disease. Intern Emerg Med. 2013;8:377-388.
111. The Writing Group for the PEPI. Effects of hormone therapy on bone mineral density: results from the postmenopausal estrogen/progestin intervention (PEPI) trial. JAMA. 1996;276:1389-1396.
112. Diamond TH, Stiel D, Posen S. Effects of testosterone and venesection on spinal and peripheral bone mineral in six hypogonadal men with hemachromatosis. J Bone Miner Res. 1991;6:39-43.
113. American College of Obstetricians and Gynecologists. Statement on results of the HERS II trial on hormone replacement therapy. Ginecol Obstet Mex. 2002;70:406-408.
114. Rossouw JE, Anderson GL, Prentice RL, LaCroix AZ, Kooperberg C, Stefanick ML, Jackson RD, Beresford SA, Howard BV, Johnson KC, Kotchen JM, Ockene J. Risks and benefits of estrogen plus progestin in healthy postmenopausal women: principal results From the Women's Health Initiative randomized controlled trial. JAMA. 2002;288:321-333.
115. Liberman UA, Weiss SR, Broll J, Minne HW, Quan H, Bell NH, Rodriguez- Portales J, Downs RW Jr, Degueker J, Favus M. Effect of oral alendronate on bone mineral density and the incidence of fractures in postmenopausal osteoporosis. The Alendronate Phase III Osteoporosis Treatment Study Group. NEJM. 1995;333:1437-1443.
116. Cohen S, Levy RM, Keller M. Risedronate therapy prevents corticosteroidinduced bone loss: a twelve month multicenter randomized double-blind, placebo-controlled parallel group study. Arthritis Rheum. 1999;42:2309-2318.
117. Wolfhagen FH, van Buuren HR, den Ouden JW, Hop WC, van Leeuwen JP, Schalm SW, Pols HA. Cyclical etidronate in the prevention of bone loss in corticosteroid-treated primary biliary cirrhosis. A prospective, controlled pilot study. J Hepatol. 1997;26:325-330.
118. Zein CO, Jorgensen RA, Clarke B, Wenger DE, Keach JC, Angulo P, Lindor KD. Alendronate improves bone mineral density in primary biliary cirrhosis: a randomized placebo-controlled trial. Hepatology. 2005;42:762-771.
119. Yurci A, Kalkan AO, Ozbakir O, Karaman A, Torun E, Kula M, Baskol M, Gursoy S, Yucesoy M, Bayram F. Efficacy of different therapeutic regimens on hepatic osteodystrophy in chronic viral liver disease. Eur J Gastroenterol Hepatol. 2011;23:1206-1212.
120. Camisasca M, Crosignani A, Battezzati PM, Albisetti W, Grandinetti G, Pietrogrande L, Biffi A, Zuin M, Podda M. Parenteral calcitonin for metabolic bone disease associated with primary biliary cirrhosis. Hepatology. 1994;20:633-637.
121. Hay JE, Malinchoc M, Dickson ER. A controlled trial of calcitonin therapy for the prevention of post-liver transplantation atraumatic fractures in patients with primary biliary cirrhosis and primary sclerosing cholangitis. J Hepatol. 2001;34:292-298.
122. Floreani A, Zappala F, Fries W, Naccarato R, Plebani M, D'Angelo A, Chiaramonte M. A 3-year pilot study with 1,25-dihydroxyvitamin D, calcium, and calcitonin for severe osteodystrophy in primary biliary cirrhosis. J Clin Gastroenterol. 1997;24:239-244.
123. Floreani A, Chiaramonte M, Giannini S, Malvasi L, Lodetti MG, Castrignano R, Giacomini A, D'Angelo A, Naccarato R. Longitudinal study on osteodystrophy in primary biliary cirrhosis (PBC) and a pilot study on calcitonin treatment. J Hepatol. 1991;12:217-223.